NCT05742919View on ClinicalTrials.gov

A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese Men

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 16, 2023

Primary Completion Date

June 13, 2023

Study Completion Date

June 13, 2023

Conditions
Non-alcoholic Fatty Liver Disease
Interventions
DRUG

NNC0194-0499

Participants will receive a single s.c. dose of 12 mg NNC0194-0499 on Day 1.

DRUG

NNC0194-0499

Participants will receive a single s.c. dose of 30 mg NNC0194-0499 on Day 1.

DRUG

NC0194-0499

Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.

Trial Locations (1)

250062

Jinan Central Hospital, Jinan

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY